US Patent Issued to DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN on Feb. 24 for "MSBI sequences as an early marker for the future development of cancer and diseases of the CNS and as a target for the treatment and prevention of these diseases" (German, Spanish Inventors)

ALEXANDRIA, Va., Feb. 24 -- United States Patent no. 12,559,770, issued on Feb. 24, was assigned to DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN (RECHTS Heidelberg, Germany).

"MSBI sequences as an early marker for the future development of cancer and diseases of the CNS and as a target for the treatment and prevention of these diseases" was invented by Ethel-Michele De Villiers-Zur Hausen (Wald-Michelbach, Germany), Harald Zur Hausen (Wald-Michelbach, Germany), Karin Gunst (Hirschberg, Germany), Corinna Whitley (Viernheim, Germany) and Iranzu Lamberto-Perez (Navarra, Spain).

According to the abstract* released by the U.S. Patent & Trademark Office: "The application relates to MSBI (Multiple Sclerosis Brain Isolate) nucleotid...